What the FDA labels say about taking them together
Atorvastatin and letermovir
Atorvastatin's FDA label of April 15, 2024 names letermovir in its drug interactions section, and letermovir's label names atorvastatin too. The letermovir label: “When PREVYMIS is co-administered with atorvastatin, do not exceed an atorvastatin dosage of 20 mg daily. Closely monitor patients for myopathy and rhabdomyolysis. …”
Check it at the source: the atorvastatin FDA label on DailyMed (effective April 15, 2024, Viatris Specialty LLC); the letermovir FDA label on DailyMed (effective January 14, 2026, Merck Sharp & Dohme LLC).
What does the atorvastatin label say about letermovir?
Atorvastatin label, drug interactionsAnti-Viral Medications Clinical Impact: Atorvastatin plasma levels were significantly increased with concomitant administration of LIPITOR with many anti-viral medications, which are inhibitors of CYP3A4 and/or transporters (…). Cases of myopathy and rhabdomyolysis have been reported with concomitant use of ledipasvir plus sofosbuvir with LIPITOR. … ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir, elbasvir plus grazoprevir or letermovir, do not exceed LIPITOR 20 mg. • In patients taking nelfinavir, do not exceed LIPITOR 40 mg [see ]. …
Source: FDA drug label (Atorvaliq, NDA213260), CMP Pharma, Inc., effective April 27, 2024 (SPL set 41fca2d8-7f3f-45b9-8974-81b89accc211), via openFDA
Source: FDA drug label (Lipitor), NDA020702 (Upjohn), as published by Viatris Specialty LLC, effective April 15, 2024 (SPL set a60cc18b-0631-4cf0-b021-9f52224ece65), via openFDA; the full label on DailyMed
What does the letermovir label say about atorvastatin?
Letermovir label, drug interactionsConcomitant Drug Class and/or Clearance Pathway/Drug Name: atorvastatin; Effect on Concentration ↓ =decrease, ↑ =increase: ↑ atorvastatin; Clinical Comments: When PREVYMIS is co-administered with atorvastatin, do not exceed an atorvastatin dosage of 20 mg daily. Closely monitor patients for myopathy and rhabdomyolysis. When PREVYMIS is co-administered with cyclosporine, use of atorvastatin is not recommended.
Source: FDA drug label (PREVYMIS), Merck Sharp & Dohme LLC, effective January 14, 2026 (SPL set 1b49df80-be4f-47e0-a0b7-123f3e69395b), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atorvastatin | Letermovir | |
|---|---|---|
| Labeled for | High cholesterol, Angina, High triglycerides, Heart attack and coronary artery disease | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.0228 per tablet 10 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once